AMGEN INC/ US0311621009 /
2024-04-26 9:05:21 AM | Chg. +0.20 | Volume | Bid5:03:45 PM | Ask5:03:45 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
250.65EUR | +0.08% | 0 Turnover: - |
252.45Bid Size: 101 | 253.25Ask Size: 148 | 135.21 bill.EUR | - | - |
GlobeNewswire
04-24
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeti...
GlobeNewswire
04-23
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire
04-15
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
GlobeNewswire
04-15
Shah Capital nominates two highly qualified independent director candidates for Novavax
GlobeNewswire
04-08
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual ...
GlobeNewswire
04-08
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Dire...
GlobeNewswire
04-05
CORRECTION -- NeuroVigil, World’s Most Valuable Neurotech Company, Launches in US
GlobeNewswire
04-04
Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth
GlobeNewswire
04-03
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engag...
GlobeNewswire
03-25
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate ...
GlobeNewswire
03-25
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Director...
GlobeNewswire
03-20
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update